Posts

J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout

on

J&J glows with $1B buyout of Firefly and its degrader platform tech: What you need to know

on

ASCO 2026: J&J shows Erleada can break prostate cancer treatment mold in high‑risk localized disease

on

J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?

on

J&J's Ottava Surgical Robot Meets Primary Endpoints in Gastric Bypass Study

on

Evolving Lymphoma Market Sidelines Two J&J CAR-T Programmes

on

AbbVie Reports Strong Skyrizi Sales Amid Wall Street Concerns Over J&J's Icotyde Pill

on

Recent Biotech News: MeiraGTx Reacquires Gene Therapy from J&J

on

Biopharma Bites: FDA Approves High-Dose Spinraza for SMA, J&J's $500M Autoimmune Deal, and Updates from BMS and Boehringer

on

J&J Targets $100 Billion in 2026 Sales Despite Stelara Patent Cliff

on

J&J Brushes Off MFN Impact, Forecasts $100 Billion Revenue Milestone for 2026

on

J&J Reports Positive Phase 3 MajesTEC-9 Results for Tecvayli in Earlier Multiple Myeloma

on

J&J's Tecvayli and Darzalex Combo Wins FDA's Proactive National Priority Voucher for Relapsed/Refractory Multiple Myeloma

on

Genmab Discontinues ProfoundBio-Derived ADC GEN1107 After Acquisition, Paralleling J&J’s Ambrx Buyout Area Developments

on

Merck Again Brings Out Big Bucks, Buys Cidara in $9.2B Antiviral Push

on

Friday Five: ESMO Looms Large, Arcus' TIGIT Revival, and J&J's Myeloma Advances

on

No Trump Drug Pricing Plan for J&J—Yet

on

Despite Government Shutdown, Companies Still Plan to Submit FDA Applications

on

J&J CAR-T Therapy Achieves 100% Response Rate in Early-Stage Lymphoma Trial

on

J&J's Akeega Advances PARP Inhibition in Prostate Cancer, but FDA Pathway in Broader Patient Subsets Remains Unclear

on